Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Tafamidis Free Acid Tablet vs Tafamidis Meglumine Capsule
NCT05498701Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-time Curve to Infinity and Maximum Observed Concentration. Started Sep 2022; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT05498701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498701.